Literature DB >> 9398058

Up-regulation of Fas (CD95) in human p53wild-type cancer cells treated with ionizing radiation.

M A Sheard1, B Vojtesek, L Janakova, J Kovarik, J Zaloudik.   

Abstract

Fas is a cell-surface protein which belongs to the tumor-necrosis-factor-receptor family. Signals through Fas are able to induce apoptosis in sensitive cells, and thus modalities for regulating the level of Fas expression on tumor cells are needed. We have studied cellular responses to gamma irradiation. The level of p53 tumor-suppressor protein was found to be elevated 3 hr after irradiation of p53wild-type MCF-7 breast-carcinoma cells. Interestingly, accumulation of p53 was followed by up-regulation of surface Fas levels between 4 and 8 hr after irradiation. The level of Fas up-regulation was dependent on dose and, whereas elevation in the level of p53 was transient, enhancement of Fas expression was stable. Fas up-regulation occurred coincidentally with induction of G1 cell-cycle arrest, a post-irradiation phenomenon known to be dependent on wild-type-p53 activity. We studied 9 other tumor lines, 2 with wild-type p53, 5 with mutant p53, and 2 expressing no p53. All lines expressing wild-type p53 were found to arrest in G1 and to up-regulate Fas after irradiation. In contrast, all 7 p53null and p53mutant lines failed not only to arrest their cell cycles in G1 phase, but also to up-regulate Fas levels in response to treatment. These findings demonstrate a direct correlation between wild-type-p53 activity and Fas up-regulation after treatment with ionizing radiation, strongly suggesting that post-irradiation Fas up-regulation is dependent on wild-type-p53 activity. Since low doses of radiation were sufficient to modulate Fas expression, up-regulation of the Fas death receptor may have clinical implications following radiotherapy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9398058     DOI: 10.1002/(sici)1097-0215(19971127)73:5<757::aid-ijc24>3.0.co;2-1

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  33 in total

1.  Gallium compound GaQ(3) -induced Ca(2+) signalling triggers p53-dependent and -independent apoptosis in cancer cells.

Authors:  Rajan Gogna; Esha Madan; Bernhard Keppler; Uttam Pati
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

2.  Gene expression profiling in MOLT-4 cells during gamma-radiation-induced apoptosis.

Authors:  Theres Lindgren; Torgny Stigbrand; Katrine Riklund; Lennart Johansson; David Eriksson
Journal:  Tumour Biol       Date:  2012-02-10

Review 3.  Targeting cell death signaling in colorectal cancer: current strategies and future perspectives.

Authors:  Bruno Christian Koehler; Dirk Jäger; Henning Schulze-Bergkamen
Journal:  World J Gastroenterol       Date:  2014-02-28       Impact factor: 5.742

Review 4.  Key mechanisms involved in ionizing radiation-induced systemic effects. A current review.

Authors:  Ifigeneia V Mavragani; Danae A Laskaratou; Benjamin Frey; Serge M Candéias; Udo S Gaipl; Katalin Lumniczky; Alexandros G Georgakilas
Journal:  Toxicol Res (Camb)       Date:  2015-08-11       Impact factor: 3.524

5.  Subtype-Specific Radiation Response and Therapeutic Effect of FAS Death Receptor Modulation in Human Breast Cancer.

Authors:  Chen-Ting Lee; Yingchun Zhou; Kingshuk Roy-Choudhury; Sharareh Siamakpour-Reihani; Kenneth Young; Peter Hoang; John P Kirkpatrick; Jen-Tsan Chi; Mark W Dewhirst; Janet K Horton
Journal:  Radiat Res       Date:  2017-06-09       Impact factor: 2.841

Review 6.  Immunomodulatory effects of radiation: what is next for cancer therapy?

Authors:  Anita Kumari; Samantha S Simon; Tomika D Moody; Charlie Garnett-Benson
Journal:  Future Oncol       Date:  2015-12-01       Impact factor: 3.404

7.  Radiation-induced tumor neoantigens: imaging and therapeutic implications.

Authors:  Christopher D Corso; Arif N Ali; Roberto Diaz
Journal:  Am J Cancer Res       Date:  2011-01-25       Impact factor: 6.166

Review 8.  Enhancing efficacy of therapeutic vaccinations by combination with other modalities.

Authors:  James L Gulley; Ravi A Madan; Philip M Arlen
Journal:  Vaccine       Date:  2007-06-04       Impact factor: 3.641

9.  In Situ Tumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments.

Authors:  Zachary S Morris; Emily I Guy; David M Francis; Monica M Gressett; Lauryn R Werner; Lakeesha L Carmichael; Richard K Yang; Eric A Armstrong; Shyhmin Huang; Fariba Navid; Stephen D Gillies; Alan Korman; Jacquelyn A Hank; Alexander L Rakhmilevich; Paul M Harari; Paul M Sondel
Journal:  Cancer Res       Date:  2016-05-06       Impact factor: 12.701

10.  The effect of cellular environment and p53 status on the mode of action of the platinum derivative LA-12.

Authors:  Eva Roubalová; Veronika Kvardová; Roman Hrstka; Sárka Borilová; Eva Michalová; Lenka Dubská; Petr Müller; Petr Sova; Borivoj Vojtesek
Journal:  Invest New Drugs       Date:  2009-06-05       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.